Eric Quéméneur
Chief Tech/Sci/R&D Officer bei TRANSGENE
Profil
Eric Quéméneur is currently the Director & EVP-Research & Development at ElsaLys Biotech SAS and the Chief Scientific Officer & Executive VP at Transgene SA. Previously, he worked as the Director-Research Programs at Comité de l’énergie Atomique from 1990 to 2014.
Dr. Quéméneur holds a doctorate degree from Université Claude Bernard Lyon 1 and an undergraduate degree from Institut National des Sciences Appliquées de Lyon, which he obtained in 1986.
Aktive Positionen von Eric Quéméneur
| Unternehmen | Position | Beginn |
|---|---|---|
| TRANSGENE | Chief Tech/Sci/R&D Officer | 01.09.2014 |
| ELSALYS BIOTECH | Chief Tech/Sci/R&D Officer | - |
Ehemalige bekannte Positionen von Eric Quéméneur
| Unternehmen | Position | Ende |
|---|---|---|
| Comité de l’énergie Atomique | Corporate Officer/Principal | 01.09.2014 |
Ausbildung von Eric Quéméneur
| Université Claude Bernard Lyon 1 | Doctorate Degree |
| Institut National des Sciences Appliquées de Lyon | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| TRANSGENE | Health Technology |
| Private Unternehmen | 2 |
|---|---|
| Comité de l’énergie Atomique | Government |
ElsaLys Biotech SAS
 ElsaLys Biotech SAS Pharmaceuticals: MajorHealth Technology ElsaLys Biotech SAS provides therapeutic monoclonal antibody player services. It involves in cellular events at the core of the pathological process: immune response, angiogenesis, survival, proliferation, adhesion and migration. The company also designs and develops a new generation of antibodies that target tumors and their immune microenvironment. ElsaLys Biotech was founded by Christine Guillen, Thierry Menguy, Vanessa Duong, and Martine Brandt in 2013 and is headquartered in Lyon, France. | Health Technology |
